Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Claritin Access Needs Study Before Other Switches Are Forced – Pfizer

This article was originally published in The Tan Sheet

Executive Summary

FDA should evaluate whether OTC Claritin has increased access and lowered costs for allergy sufferers before deciding whether to require the other second-generation antihistamines to switch OTC, Pfizer asserts in May 7 comments to the agency
Advertisement

Related Content

Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan
OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

Topics

Advertisement
UsernamePublicRestriction

Register

PS095508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel